A detailed history of Neuberger Berman Group LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 82,733 shares of PCVX stock, worth $7.33 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
82,733
Previous 108,092 23.46%
Holding current value
$7.33 Million
Previous $8.16 Million 15.72%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $1.79 Million - $2.97 Million
-25,359 Reduced 23.46%
82,733 $9.45 Million
Q2 2024

Nov 14, 2024

BUY
$60.06 - $78.77 $347,206 - $455,369
5,781 Added 5.65%
108,092 $8.16 Million
Q2 2024

Aug 13, 2024

BUY
$60.06 - $78.77 $347,206 - $455,369
5,781 Added 5.65%
108,092 $8.16 Million
Q1 2024

Nov 14, 2024

BUY
$59.79 - $81.05 $965,249 - $1.31 Million
16,144 Added 18.74%
102,311 $6.99 Million
Q1 2024

May 13, 2024

BUY
$59.79 - $81.05 $6.12 Million - $8.29 Million
102,311 New
102,311 $6.99 Million
Q4 2023

Nov 14, 2024

SELL
$45.35 - $63.41 $994,298 - $1.39 Million
-21,925 Reduced 20.28%
86,167 $5.41 Million
Q4 2023

Feb 09, 2024

BUY
$45.35 - $63.41 $905,911 - $1.27 Million
19,976 Added 30.18%
86,167 $5.41 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $60,168 - $69,454
1,308 Added 2.02%
66,191 $3.37 Million
Q2 2023

Aug 11, 2023

BUY
$34.66 - $54.07 $1.2 Million - $1.87 Million
34,658 Added 114.67%
64,883 $3.24 Million
Q1 2023

May 12, 2023

BUY
$36.27 - $47.2 $92,089 - $119,840
2,539 Added 9.17%
30,225 $1.13 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $569,777 - $1.33 Million
27,686 New
27,686 $1.33 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.25B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.